Abstract: Nitric oxide (NO) is an endogenously-produced small molecule that has critical roles in cellular signaling and a variety of physiological processes in many tissues, including the brain, the vasculature, and the immune system. In several medical disorders, NO has been implicated in disease pathology, in most cases due to persistent activation or overproduction of one of three NO synthase (NOS) isoforms. Although NOS inhibitors that are both potent and cellpermeable have been developed, none is currently used in the treatment of any disorder. One reason that NOS inhibitors fail to have therapeutic efficacy may be linked to their very low isoform-selectivity. An additional possibility is that NOS inhibitors, even if they exhibit isoform selectivity, might indiscriminately affect beneficial and pathological NO signaling pathways. In this review, we discuss emerging approaches in the development of isoform-specific NOS-directed therapeutics including dimerization inhibitors, novel L-arginine (L-Arg) binding site inhibitors, and dimer stabilization. Additionally, we suggest novel strategies for the future including targeting subcellular localization of NOS and proteinprotein interactions with NOS effectors.
INTRODUCTION
NO is a highly reactive signaling molecule that is made in a wide variety of cells, most prominently neurons, skeletal muscle, endothelial cells, and certain immune system cells. In these cells, NO is synthesized by one or more of three highly related NOS isoforms, neuronal NOS (nNOS, or NOS-1), endothelial NOS (eNOS, or NOS-3), and macrophage or inducible NOS (iNOS, or NOS-2), each of which is encoded by a separate gene. Although each NOS isoform is named for the cell type in which it was first isolated, none is confined to any one cell type and most cells express more than one isoform [1] .
NO has numerous critical roles in the body, including maintaining blood pressure, acting as a neurotransmitter in the brain, and as a key component of the immune system's repertoire of antiviral and antibacterial agents. However, misregulation and overproduction of NO can occur, and overproduction contributes to the pathogenesis of a range of diseases. In principle, since inhibitors of NOS are readily available, they should have an important role in the treatment of numerous NO-related diseases. However, clinical trials of NOS inhibitors so far have either failed or produced equivocal results. The failure of NOS inhibitors may reflect a failure of the NOS inhibitors to selectively inhibit specific isoforms. An alternate possibility is that NOS blockade impairs critical salutatory effects of NO. Thus, new strategies for NOS inhibition and new types of NOS inhibitors are needed.
In this review, we describe evolving strategies for inhibiting NO production in disease. A major focus of current research efforts is the development of isoformselective inhibitors. We describe strategies for isoformselective NOS inhibitors, such as NOS dimerization inhibi-*Address correspondence to this author at the Department of Pharmacology, Weill Medical College, Cornell University, New York, NY 10021, USA; Email: srj2003@med.cornell.edu tors, and discuss potential pitfalls with these approaches, including potentially inhibiting essential functions of NO. We also describe newer strategies that might more selectively inhibit the pathologic effects of NO by modulating interactions of NOS isoforms with specific intracellular protein binding partners.
REGULATION OF NOS IN NORMAL AND DI-SEASE STATES
NO generation in cells is highly regulated. NOS isoforms are heme-containing proteins that synthesize NO from L-Arg and NADPH [2] in an O 2 -dependent reaction [3] (Fig. 1) . The NOS isoforms are expressed as inactive monomers. The active enzyme is referred to as a homodimer but is technically a tetramer composed of two NOS monomers each bound to a calmodulin (CaM) which is essential for enzyme function [4] . Each monomer exhibits a bidomain structure composed of an N-terminal oxygenase domain linked by a CaM-binding site to a C-terminal reductase domain (Fig. 2) . In the case of eNOS and nNOS, increases in intracellular calcium regulate NO synthesis by triggering the binding of calcium-CaM complexes to the NOS dimer. This binding results in conformational changes that enhance enzymatic coupling of the NOS reductase domain to the oxygenase domain [5] . In the case of iNOS, the calciumCaM complex is constitutively bound regardless of ambient calcium concentrations, resulting in high levels of NO production by cofactor-replete iNOS [6] . Because iNOS is constitutively active, NO synthesis in cells that express iNOS is thought to be regulated at the level of transcription, translation, and protein degradation [7] .
NOS enzymes are enzymatically active as dimers, with the oxygenase domain mediating dimerization. Unlike the reductase domain, which is highly conserved between the isoforms, the oxygenase domain displays the highest level of variation among the different isoforms [8] . Additionally, the oxygenase domain contains binding sites for L-Arg, tetrahydrobiopterin (BH 4 ), and heme, which are all required for enzyme activity. The reductase domain, on the other hand, contains binding sites for FAD, FMN, and NADPH (Fig. 2) . There is also a high degree of homology between the NOS reductase domain and the cytochrome P-450 enzyme family [9] .
NO has numerous roles in normal signaling and physiological function. However, in certain diseases, these normal actions occur concomitantly with overproduction and nonspecific tissue damage, or misregulated activation of NOdependent signaling pathways. Because the three NOS isoforms have markedly different mechanisms of regulation, tissue distributions, and physiological functions, it follows that the pathological conditions associated with excess NO are also isoform specific. For example, NO production in neurons is linked to neurotransmitter-dependent calcium signaling. However, in numerous neurodegenerative diseases, calcium homeostasis is impaired [10, 11] , leading to inappropriate activation of nNOS. Using mice harboring a genomic deletion in the nNOS gene (nNOS -/-), or NOS inhibitors that exhibit partial selectivity for nNOS, nNOS has been implicated in the animal models of numerous neurodegenerative diseases, such as stroke [12] , Parkinson's disease [13] [14] [15] , Huntington's disease [16] , and amyotrophic lateral sclerosis [17] .
In addition to nNOS, iNOS has been implicated in numerous disorders. iNOS is induced in cells in response to various inflammatory stimuli such as tumor necrosis factor (TNF), interferon-gamma, or lipopolysaccharide [18] . Although iNOS induction has key roles in the innate immune system due to the anti-viral and anti-bacterial effects of NO, the large amounts of NO produced by iNOS also contribute to tissue damage seen in autoimmune and inflammatory diseases such as asthma and rheumatoid arthritis [19] , and contributes to the hypovolemia and impaired tissue perfusion in sepsis [20] .
eNOS, on the other hand, is largely considered to be beneficial due to its role in vasodilation, and misregulation of its activity is generally not thought to be a major contributor to disease. Thus, most of the interest in NOS inhibition focuses on iNOS and nNOS.
When considering NOS inhibitors as therapy, it is important to keep in mind that the synthesis of NO during disease activates signaling pathways that have beneficial effects in limiting disease progression. Disruption of these beneficial effects might limit the medical usefulness of NOS inhibitors. One key effect of NO is to reduce the susceptibility of cells to oxidative damage from agents such as hydrogen peroxide and hydroxyl radical. Basal levels of NO expression reduce the susceptibility of endothelial cells to reactive oxygen species [21] . In the brain, nNOSexpressing cells are surprisingly resistant to excitotoxins and persist in neurodegenerative diseases such as Huntington's disease and Alzheimer's disease [22] , conditions which are associated with oxidative neuronal injury. Additionally, nNOS expression is rapidly induced in a variety of CNS and PNS neurons following several types of nerve injury [23] [24] [25] . This induction of nNOS may reflect a requirement for NO in axon outgrowth or as a protective response to injury. Cytokine-induced iNOS protects hepatocytes from peroxides [26] and promotes wound healing [27] . These effects of NO are thought to be related to NO-dependent induction of antioxidant genes such as heme oxygenase-1 and Mn superoxide dismutase [28] . NO also represses NF-kappa B, a critical inducer of the inflammatory response [29] , regulates cytokine production, and stimulates T-helper cell expansion [30] . A mechanism for increased cellular resistance to oxidants in NO-synthesizing cells could be due to direct inhibitory effects of NO on the caspases that trigger apoptosis [31] . The antiapoptotic effects of NO may also be related to direct regulation of mitochondrial respiration and cytochrome C [32] [33] [34] [35] . In addition to these antioxidant and pro-survival effects, NO production may also be critical for increasing tissue perfusion, which would improve access for immune system cells and would lead to greater tissue oxygenation, reducing ischemia-related oxidative damage. Thus, NO has critical roles in cell survival, and disruption of these effects could adversely affect disease morbidity or mortality.
In addition to these cytoprotective effects, NO generated in endothelial cells has important beneficial effects on the vasculature. eNOS-produced NO from endothelial tissue causes relaxation of the vasculature, inhibits platelet adhesion, promotes angiogenesis, and prevents smoothmuscle cell hyperplasia [36] . Absence of eNOS activity, either genetically or pharmacologically, results in hypertension, inappropriate response to vascular injury, enhanced platelet activation, atherogenesis and aneurysms [37, 38] . eNOS also has protective roles in disease. For example, lipopolysaccharide-treated animals exhibit microvascular damage which is manifested as plasma leakage into tissue [39] . This leakage is enhanced by eNOS inhibition [40] , thus identifying a role for eNOS in protecting against microvascular injury during stress. As a result, finding isoform-specific NOS inhibitors which exhibit very low inhibition of eNOS activity is important to avoid introducing complications in endothelial cells and the vasculature.
NOS INHIBITORS IN NO-RELATED DISEASES
Although both iNOS and nNOS have been implicated in several disease states, NOS inhibitors are not currently used for the treatment of any disorder, and studies that have examined the use of NOS inhibitors have not demonstrated therapeutic efficacy [41] . In addition to inhibiting the beneficial effects of NO, one possible explanation is the lack of isoform selectivity of the NOS inhibitors that have been examined to date. An example of this appears in stroke models where nNOS is thought to become overactive in response to cerebral ischemia. Potent nNOS inhibitors such as L-N G -nitroarginine (L-NA) ( Table 1 ) have had limited success in preventing post-ischemic injuries in rats, especially when compared to the stroke resistance of the nNOS -/-mouse [10, 11] . The inability of L-NA to reduce post-ischemic damage might reflect its ability to inhibit 
eNOS, which is inhibited with similar potency [42] . Inhibition of eNOS results in vasoconstriction, which reduces blood flow, further exacerbating brain ischemia [43] . As a result, nonselective inhibitors are likely to cause added cerebral damage. Thus, when considering neurodegenerative diseases and stroke, which are exquisitely sensitive to decreases in perfusion, nNOS-selective inhibitors will be critical for achieving therapeutic efficacy.
NOS inhibitors have also not been shown to be effective for treatment of sepsis. In sepsis, bacterial lipopolysaccharide induces the production of large amounts of iNOS and NO, which causes massive vasodilation and hypotension, leading to hypoperfusion and multiorgan failure. Treatment with the nonselective NOS inhibitor N-methylarginine (L-NMMA) ( Table 1 ) reduced shock, i.e., vasodilation and hypoperfusion; however, this did not lead to a reduction in mortality [44] . Indeed, treatment resulted in increased mortality [44] . Although the basis for the increased mortality seen with the NOS inhibitor, is not clear, one possibility is that it could be a result of the nonselectivity of L-NMMA. For example, eNOS or nNOS could have critical roles in homeostasis during sepsis, and inhibition of these isoforms might have led to impaired survival. An alternate possibility is that the increased mortality associated with L-NMMA treatment does not reflect inhibition of eNOS or nNOS, but reflects inhibition of critical iNOS-dependent anti-sepsis responses. Assessment of the effects of iNOSselective inhibitors in sepsis will be required to resolve whether the absence of isoform-selective NOS inhibition accounts for the increased mortality of L-NMMA -treated patients.
Currently, it is not clear whether the pathologies of sepsis, stroke, or other diseases would benefit from isoformselective inhibition, or whether isoform selective inhibition would fail due to inhibition of beneficial effects of NOS. A critical step towards addressing this question is the development and testing of isoform-selective NOS inhibitors. Strategies for isoform-selective NOS inhibition, as well as alternative approaches that target specific NOS pathways, are described below.
L-ARG-BINDING SITE INHIBITORS
Traditionally, enzyme inhibitors have been designed to mimic endogenous substrates. This approach is considerably more difficult when there are multiple enzymes that utilize the same substrate, and the goal is to obtain selectivity among a group of related isoforms, as in the case of obtaining NOS isoform-selective inhibitors. For example, potent NOS inhibitors have been identified that contain guanidine [45] , amidine [46] , or isothiourea [47] moieties that mimic the binding mode of the endogenous guanidinecontaining L-Arg substrate. Although potent, with IC 50 (halfmaximal inhibitory concentration) values in the low micromolar range, these inhibitors show little if any selectivity between NOS isoforms [48] . Initial crystal structures of iNOS and eNOS bound to simple L-Arg analogues revealed a highly similar active site [49] , and suggested few approaches for structural modifications of LArg analogues that could confer selectivity. However, recent data has shown that L-Arg analogues that contain elongated appendages can confer significant isoform selectivity, presumably by extending out of the L-Arg binding pocket to interact with less conserved residues. These "far-reaching" L-Arg-site inhibitors have revealed several promising routes toward gaining selectivity at the NOS substrate-binding site [48] .
iNOS-Selective
L-Arg derivatives that show high specificity toward iNOS inhibition have been identified. To date, the most isoform-selective of these compounds is 1400W, a carbamidine-containing small molecule, which is a mechanismbased iNOS inhibitor with an IC 50 value of 0.23 µM [40] ( Table 2) . 1400W has an isoform selectivity ratio (the ratio of IC 50 values) of 32 for iNOS over nNOS and ~4000 for iNOS over eNOS [50, 51] . Importantly, 1400W displays NADPH-and time-dependent inhibition with minimal or no reversibility [40] . Crystal structures of 1400W bound to all three isoforms have been solved, and have suggested the mechanism of isoform selectivity [50, 51] . 1400W binds in the L-Arg binding pocket, interacting with Glu-371, an isoform conserved residue that usually hydrogen bonds with the guanidine hydrogens of L-Arg. 1400W also has interactions with two heme propionate moieties, which are enabled by a subtle conformational shift in the active site that permit the simultaneous interaction of 1400W with both Glu-371 and the propionates. This conformational shift also positions the carbamidine carbon over the iron atom in the heme moiety. These interactions may be critical for the reduced affinity towards the eNOS isoform since in the case of 1400W bound to eNOS, the interaction with the heme propionates was absent [50, 51] . The interpretation is complicated somewhat by the absence of bound BH 4 in the eNOS structure, which may have affected the bound conformation of W1400. Alternatively, 1400W might interact exclusively with the BH 4 -deficient enzyme, a form which is not highly abundant in vivo. In the case of nNOS, 1400W binds both the Glu-371 and heme propionates but seems to bind iNOS more tightly than nNOS due to the flexibility of a conserved glutamate residue found in iNOS. In nNOS, this glutamate residue is much more conformationally restricted, preventing the 1400W-induced conformational shifts resulting in different positioning the carbamidine carbon relative to the heme iron (Fig. 3A, B) . Although the mechanistic basis for 1400W inhibition is not known, the crystallographic data supports a model in which the heme-hydroperoxy intermediate radicalizes the carbamidine carbon by hydrogen extraction, leading to heme modification and/or cleavage, similar to P450 suicide inhibitor mechanisms [50, 51] . 1400W selectivity may be achieved by a combination of high affinity binding to iNOS through interactions within and outside the traditional L-Arg binding pocket, as well as highly efficient 1400W radicalization and mechanism-based inactivation, due to the high-output substrate turnover that is characteristic of this isoform [50, 51] . GW273629 and GW274150 [52] are two more highly selective iNOS inhibitors which have generated much interest recently for their success in treating several animal models of disease [53] [54] [55] [56] . However, the mechanism underlying their selectivity is still unknown. Other promising iNOS-specific inhibitors have also been identified from several other families of compounds, including 2-aminopyridines [57] , L-N6-(1-iminoethyl)lysines [58, 59] , aminoguanidines [45, 60] , iminopyrrolidines [61] , spiroquinazolones [62, 63] However, while these compounds exhibit good selectivity for iNOS over eNOS, many suffer from poor selectivity of iNOS over nNOS ( Table 2) .
The latest advances in L-Arg-site inhibitors have been from a novel class of compounds based on an imidazopyridine backbone. These compounds have recently yielded a highly potent iNOS inhibitor, BYK191023, which is ~2000-fold and ~200-fold more selective for iNOS over eNOS and nNOS, respectively [64] ( Table 2) . BYK191023 binding is competitive with L-Arg [64] and thus is thought to inhibit via binding to the L-Arg-binding site. To date, no crystal structures of the BK191023-iNOS interaction have been solved, and no mutagenesis studies have been reported to provide insight into the mechanism of inhibition. However, while BYK19023 most likely binds to the L-Arg site, the large heterocyclic backbone of this and other imidazopyridine derivatives suggests that far-reaching interactions play a key role in their iNOS selectivity. An additional advantage of these imidazopyridine compounds is that they did not show any toxicity in various human cell lines even up to high micromolar concentration [64] and BYK191023 was beneficial in treating animal models of ischemia [65] , making imidazopyridine derivatives another promising possibility for future therapeutics. [66] and N-propyl-L-Arg (L-NPA) [67, 68] ( Table 3) , have recently been reported as nNOS-selective mechanism-based inhibitors in a manner similar to that of 1400W [40] . Both compounds are simple L-Arg-related molecules with only one small chemical variation: the guanidine group is substituted with a short hydrocarbon chain. The identification of these nNOS selective inhibitors is very promising since they suggest that selectivity for nNOS can be gained with only modest changes to the structure of the L-Arg sidechain. Of these two compounds, L-NPA is the more promising inhibitor with a K i (inhibitor dissociation constant) in the low nanomolar range and a selectivity ratio of 149 with respect to eNOS and 3158 with respect to iNOS [67] . Crystal structures of L-NPA bound to iNOS and nNOS have revealed that the inhibitor interacts with residues just outside of the L-Arg binding pocket [50] , and it is these far-reaching interactions that direct selectivity (Fig. 3C, D) . Although even greater specificity for nNOS over eNOS is necessary for therapeutic utility, these compounds demonstrate that it is possible to gain specificity with L-Arg-analogues by merely regulating the size and geometry of the side chain.
nNOS-selective
In addition to the L-Arg analogues, several inhibitors without significant structural similarity to L-Arg have also been developed that selectively bind the L-Arg-binding site of nNOS. Perhaps the most promising of these are the isothioureas, such as S-ethylisothiourea, which emerged early as potent and semi-selective inhibitors of NOS [69] that compete with L-Arg for NOS binding [70] . The primary problem with these compounds has been their poor cellular penetration and only modest isoform selectivity. In addition, development of these compounds was often precluded by toxic effects, as was the case with the iNOS selective bisisothioureas ( Table 2) , which also inhibited Na + /K + ATPases [71] . However, more recent isothiourea derivatives targeted toward nNOS, such as AR-R17477 (also referred to as ARL 17477) and its derivatives, have improved on both of these problems by exhibiting 300-fold selectivity for nNOS over eNOS ( Table 3) and showing improvement in cellular penetration [72] . AR-R17477 has shown neuroprotective effects in animal models of cerebral ischemia [73] [74] [75] , suggesting a possibility for future therapeutics. Crystallography studies have revealed that a single residue difference is responsible for the isoform selectivity of AR-R17477 for iNOS over nNOS [76] . The selectivity-conferring residue, Leu-337, which corresponds to Asn-115 in iNOS, is just outside of the substrate binding pocket, and stabilizes a chlorophenyl moiety in AR-R17477 (Fig. 3E, F) . Thus, AR-R17477 provides another example for how far-reaching LArg-site inhibitors can show significant selectivity.
Progress in the development of nNOS-selective inhibitors has also been made with derivatives of 6-phenyl-2-aminopyridine [77, 78] , nitroarginine-containing dipeptides [79, 80] and dipeptidomimics [81] , and nitroindazoles [82] ( Table 3 ).
DIMERIZATION INHIBITORS
Small molecules that either disrupt or prevent the formation of the NOS dimer might be useful to obtain isoform-selective inhibitors. Each of the NOS isoforms requires dimerization for enzymatic function, although the dimer interface displays less structural conservation than the catalytic sites. When NOS monomers first associate they form "loose dimers" in a process that is initiated by the coordination of a heme iron to a cysteine residue in each monomer [83] [84] [85] . These loose dimers cannot synthesize NO [86] , have their active sites exposed [87] , and are more susceptible to proteolysis [88] . Dimerization induces conformational changes that result in the creation of binding sites for L-Arg and BH 4 [89] . The binding of L-Arg and BH 4 converts these loose dimers into stable, "tight dimers" which are then competent for NO catalysis [90] . NOS enzymes are only fully functional as homodimers because electrons must flow from the reductase domain flavins of one monomer to the oxygenase domain heme of the other monomer. Conceivably, small molecules that bind to the dimerization interface or molecules that interfere with heme-induced or heme-stabilized dimerization could prevent NOS from adopting the dimerized conformation.
Considerable precedent exists for dimerization inhibitors that function by binding the enzyme-bound heme. For example, clotrimazole and miconazole, both of which are anti-fungals that contain imidazole moieties, inhibit NOS isoforms by binding reversibly to the heme in NOS monomers [91] . The imidazole nitrogen binds to the heme moiety in the sixth axial position, and distorts adjacent residues that would otherwise participate in dimer formation [91] . The antifungals are bulky, and this bulkiness is required for their inhibitory activities, while smaller imidazoles, such as 7-nitroindazole, are capable of binding to iNOS-bound heme, but do not affect dimerization [91] . These antifungal imidazoles can also inhibit preformed In iNOS, Thr-277 (not shown) is found instead of Asn at this position and is too short to interact with the guanidinium group of Arg-260 (closed white arrow). This allows Arg-260 to drop into the binding pocket and interact with Gln-257, preventing hydrogen bond formation between Gln-257 and N _ -propyl-L-arginine. E, F, (PDB-identifiers: IVAG, IVAF) Structures of nNOS-selective inhibitor AR-R17477 bound to the heme-containing oxygenase domains of rat nNOS (E) and murine iNOS (F). Leu-337 (closed arrow) found in nNOS stabilizes the hydrophobic chlorophenyl moiety of AR-R17477 (open arrow). In iNOS, the hydrophilic residue Asn-115 (closed arrow) is found at this position and results in destabilization of the chlorophenyl group indicated by two alternating positions (open arrow). G, (PDB-identifier: IDD7) Structure of dimerization inhibitor BBS-2 (yellow backbone) bound to murine iNOS ∆114. The imidazole ring of BBS-2 coordinates directly to the heme moiety (cyan backbone) and its amide nitrogen hydrogen bonds with one of the heme propionates. BBS-2 binding is further stabilized by hydrogen bonding between its carbonyl and two water molecules (magenta) which, in turn, are hydrogen bonded to Gln-257 (green) and Tyr-367 (orange). Of interest is the displacement of the highly conserved Glu-371 (not shown) which is essential for enzyme function. H, (PDB-identifier: INOS) Structure of murine iNOS ∆114 cocrystallized with heme (cyan backbone) and two imidazole molecules (yellow backbone). Gln-257 (green) and Tyr-367 (orange) are found in similar positions to those seen in G, but the two water molecules (Fig. 3) Ligand Contd…. which stabilize BBS-2 binding are absent. Importantly, Glu-371 (purple) is found in the same position as for active dimers, suggesting that BBS-2, and not truncation, led to Glu-371 displacement. I, (PDB-identifiers: IDD7 and INOS) Comparison of the BBS-2-iNOS ∆114 (blue) with the imidazole-iNOS ∆114 structure (orange). The heme (cyan backbone) from the BBS-2-iNOS ∆114 complex is shown as well as BBS-2 (yellow backbone). Differences in the conformation of the dimer interface (closed arrow) can be seen. dimers, although this inhibition is prevented by L-Arg and BH 4 [91] , which bind to sites adjacent to the heme, and appear to block binding of these inhibitors.
In an attempt to identify more potent and selective inhibitors of iNOS that utilized this pathway, McMillan et al. [92] screened a combinatorial library based on a pyrimidine imidazole scaffold for iNOS inhibitors. Although none of the compounds inhibited iNOS in in vitro assays, several inhibitors were identified in cell-based assays in which NO release was measured in cells that expressed iNOS in the presence of compounds from the library. In the case of one of these compounds, BBS-2 ( Table 4) , an explanation for the selective inhibition of NOS activity in cells but not in vitro was suggested by the finding that BBS-2-treated cells contained a significant fraction of iNOS in the monomeric form, and BBS-2 was able to prevent iNOS monomers from forming dimers in vitro. Thus, BBS-2 was proposed to prevent newly synthesized iNOS monomers from forming functional iNOS dimers. Like antifungal imidazole compounds, BBS-2 coordinates directly to the heme in the sixth axial position [92] , however, unlike antifungal imidazoles, BBS-2 had no effect on preformed dimers. BBS-2 binds iNOS monomers with K i and IC 50 values in the low nanomolar range and is >1,000-fold selective for iNOS over eNOS in cell-based assays [93] . Interestingly, BBS-2 binding to iNOS also inhibits iNOS translation [94] , apparently by binding to iNOS as it emerges from the ribosome, and stalling mRNA translation. This results in reduced total levels of iNOS, further reducing total cellular iNOS activity [94] .
Since the heme moiety is physically distinct from the dimerization interface, it is not immediately clear how BBS-2 binding would affect iNOS dimerization. The mechanism of BBS-2-mediated inhibition of dimerization was suggested by the BBS-2-iNOS cocrystal structure [92] . This structure was determined by soaking BBS-2 into crystals of a truncated oxygenase domain of murine iNOS (iNOS ∆114). This truncated form of iNOS, missing the first 114 residues, had previously been reported to crystallize as monomers when bound to imidazole [95] . Compared to the imidazolebound iNOS ∆114 structure, the BBS-2-iNOS ∆114 complex revealed several key allosteric changes (Fig. 3G-I) . These conformational changes include repositioning residues involved in L-Arg and BH 4 binding as well as those at the dimer interface. While primarily bound to the heme moiety, BBS-2 also occupies part of the L-Arg binding site, leading to displacement of residues critical to substrate binding [92] . Most significant might be the disruption of helix 7a which contains Glu-371, the isoform-conserved residue that forms hydrogen bonds with the guanidino group of L-Arg. This interaction between Glu-371 and L-Arg is essential for aligning the guanidino nitrogen with the O 2 molecule coordinated by the heme moiety during normal catalysis, and has key roles in stabilizing the iNOS dimer [96, 97] . The authors of the study suggest that BBS-2 displaces Glu-371 leading to general disorder in helix 7a. This distortion may lead to the conformational changes seen in other nearby residues, including helix 8, which is part of the dimer interface and residues 460-462 which contribute to the binding of BH 4 . Because Glu-371 is conserved in all NOS isoforms, crystal structures of BBS-2 bound to iNOS, and possibly eNOS, will be needed to elucidate how BBS-2 gains its selectivity.
Thus, the mechanism behind the isoform selectivity of BBS-2 is still somewhat elusive. In fact, a recent report by Habisch et al. suggests that BBS-2 may not be as isoformspecific as once believed [98] . By infecting cells with a recombinant adenovirus containing the cDNA of nNOS, the authors show that BBS-2 (referred to as BBS-1 in [98] ) also inhibits nNOS activity with an IC 50 of 40 nM [98] . The experiments also reveal that BBS-2 reduces formation of SDS-resistant nNOS dimer (an assay for tight dimers) while having a minimal effect on the activity of preformed nNOS dimers [98] . BBS-2 was not found to significantly inhibit eNOS dimerization [98] . Thus, further clarification will be required to fully assess the selectivity of BBS-2 for iNOS over nNOS.
In addition to BBS-2, another imidazole-based iNOS dimerization inhibitor, PPA250, has been described which similarly prevents dimerization of iNOS monomers but does not affect preformed iNOS dimers [99] ( Table 4 ). The success of this class of iNOS inhibitors raises the question of whether these molecules are better than L-Arg-binding site iNOS inhibitors that exhibit similar degrees of isoform selectivity. A practical concern with these dimerization inhibitors is that when therapy is begun for iNOS inhibition, there will be no immediate effect on NO synthesis since preexisting iNOS will not be affected. Thus, NO levels will drop at a rate that reflects the degradation rate of preexisting iNOS. In diseases such as septic shock, where rapid therapeutic intervention is required, this may not be acceptable; however, in chronic inflammatory or autoimmune disorders, the delay in iNOS inhibition may be acceptable. Additionally, because these compounds are imidazole analogues, a class of compounds used as chemotherapeutic agents [100] , it is important to confirm that they are not interacting with other heme-containing proteins such as members of the P-450 enzyme family.
A future direction for the development of dimerization inhibitors would be to target the dimerization interface directly rather than to allosterically affect dimerization by binding heme. As mentioned above, the dimerization of two NOS monomers into an active enzyme involves a large interface in the oxygenase domain. This interface contains the highest variability between isoforms, providing an excellent target for isoform-selective drugs. Evidence that the contacts made between two NOS monomers are highly isoform specific has been shown by crystal structures of dimerized NOS oxygenase domains [101] [102] [103] . Biochemical data has also shown stability differences between the three NOS dimers [96] . Under various denaturing conditions, eNOS proved to be much more stable than nNOS, and nNOS was more stable than iNOS [96, 104] . Furthermore, the dimers also differed in their ability to be stabilized by L-Arg and BH 4 binding [96, 97] . In all of these experiments, eNOS dimers were markedly more stable than nNOS and iNOS dimers. Yeast two-hybrid studies have shed some light on how these differences may result by suggesting that, for iNOS, only the oxygenase domain is involved in dimer formation, whereas for nNOS and eNOS, there are interactions between the reductase domains as well as between the reductase and oxygenase domains of the different monomers [104] . These stability differences between the NOS isoforms identify isoform-unique residue interactions involved in dimerization. Conceivably, these unique interactions can be targeted with small molecules, resulting in inhibitors with much higher isoform selectivity. These compounds could be identified in cell-based library screens that monitor the formation of iNOS activity after treatment with molecules like lipopolysaccha-ride, as was used to identify BBS-2 [92] . Alternatively, in vitro translation systems, such as rabbit reticulocyte lysate systems, could be programmed with cyan fluorescent protein (CFP) and yellow fluorescent protein (YFP)-tagged iNOS mRNAs, and iNOS inhibitors could be identified by their ability to block fluorescence resonance energy transfer between YFP-and CFP-iNOS dimers. The compounds that bind the dimer interface would have the advantage of avoiding any toxicity due to heme binding.
DESTABILIZING VS. STABILIZING NOS DIMERS
In addition to NO, NOS isoforms are also capable of producing superoxide under certain circumstances. NOSgenerated superoxide requires CaM binding and hemeassociated dimers, but does not require L-Arg or BH 4 . Indeed, provision of BH 4 or L-Arg inhibits superoxide production by NOS [105] . Superoxide production is thought to reflect NADPH-dependent reduction of heme-bound oxygen to a ferric superoxide complex, which in the absence of reaction with L-Arg, dissociates to generate superoxide [105] . The binding of both L-Arg and BH 4 reduces the rate of dissociation of superoxide [106] . Superoxide production can be inhibited by L-Arg analogue NOS inhibitors, such as N G -nitro-L-arginine methyl ester (L-NAME), although some inhibitors can actually augment superoxide production [107] . Superoxide production by NOS can be more cytotoxic than NO production, since NO undergoes limited reactions with proteins and DNA, while superoxide, and peroxynitrite, generated by reaction of NO and superoxide, are highly efficient oxidants that nonspecifically modify numerous biological molecules [108] .
Although numerous studies have demonstrated that NOS contributes to disease pathology, the experimental approaches that have been used to make these conclusions, involving either application of NOS inhibitors or the use of NOS knockout approaches, do not distinguish between the role of NOS-generated NO or NOS-generated superoxide as the mediator of toxicity. Superoxide is generated by a variety of cell types, such as neurons and macrophages [109] , and various disease states associated with increased or persistent NOS activation are associated with decreased intracellular The IC50 values of different inhibitors might not be directly comparable because the values depend on the amount of substrate (L-arginine) used in each study. eNOS, endothelial nitric oxide synthase; IC50, half-maximal inhibitory concentration; iNOS, inducible nitric oxide synthase; nNOS, neuronal nitric oxide synthase.
levels of L-Arg [110, 111] or BH 4 [111] [112] [113] , providing environments conducive to superoxide production. Superoxide readily reacts with NO to produce peroxynitrite, a highly reactive oxidant [114] . Indeed, tyrosine nitration in proteins is largely due to reaction with peroxynitrite, not NO, and is a common finding in diseases associated with excess NOS activation [115] . Thus, superoxide may be the critical factor in mediating the cytotoxicity associated with excess NOS activity.
Thus, a strategy to treat NOS-related diseases may be to reduce superoxide production by provision of L-Arg or BH 4 , or by small molecules that allosterically enhance their affinity. This would lead to increased NO production, and ameliorate NOS toxicity if disease is due to superoxide or peroxynitrite, rather than NO production [116] . Indeed, there are several examples where L-Arg or BH 4 , which increase NO production, ameliorate the pathology of conditions typically thought to be due to excess NO. For example, in sepsis, which is associated with excessive iNOS induction [117, 118] , L-Arg supplementation reduces mortality [119, 120] . Similarly, in diabetes-related vasculopathy, endothelial cells release decreased NO and increased reactive oxygen species [121] , and L-Arg supplementation improves hemodynamics [122, 123] . In the case of 1-methyl-4-phenylpyridinium (MPP+)-induced neurotoxicity in the substantia nigra, which is mediated in part by nNOS-dependent neurotoxicity, sepiapterin, a precursor of BH 4 , significantly reduces neuronal death [124] . In some reports, L-Arg supplementation reduces infarct volume during stroke [125] , although these results have not been found in all studies [126] . Therefore, in many cases, maintaining NO synthesis and stabilizing NOS dimers, rather than inhibiting NOS, may prove to be a more useful therapeutic intervention.
In addition to providing natural substrates, various BH 4 mimics that promote NO production may be very useful in situations where natural substrate levels are low. BH 4 allosterically increases the affinity of NOS for L-Arg [83, 84, 96, 127, 128] , which could increase L-Arg uptake in environments of low L-Arg concentrations. Providing BH 4 mimics as opposed to the natural substrate could increase cell-permeability and avoid unwanted side effects of increased BH 4 levels in the body [129, 130] . The NOS BH 4 -binding site also differs structurally compared to other BH 4 -containing enzymes such as aromatic amino acid hydroxylases [131] , providing a mechanism for gaining selectivity for NOS. Although most molecules that target the BH 4 site have inhibited rather than augmented NO synthesis [132] , some BH 4 analogues support NO synthesis. For example, the BH 4 analogue, 5-methyl H 4 -biopterin supports NO production by NOS, and is associated with substantially less superoxide production compared to BH 4 [133] .
TARGETING INTERACTIONS OF NOS ISO-FORMS WITH BINDING PARTNERS
The failure of NOS inhibitors to provide clinical benefit in sepsis and other medical disorders has prompted efforts to develop isoform-selective NOS inhibitors. There is a great deal of precedent for improving drug efficacy and reducing side effects by improving target selectivity. However, NOS isoforms are different from many other enzymes due to the highly pleiotropic effects of the enzyme product, i.e., NO. As described earlier, the induction of NO in many diseases has pathogenic effects, which need to be inhibited, but may also have critical homeostatic effects which would be unwise to inhibit. A key example of this occurs during sepsis, where the effects of iNOS are highly diverse and inhibiting iNOS is expected to lead to a combination of beneficial and detrimental effects on organ function [134] . A solution to this problem is the use of molecules that inhibit specific NOS effector pathways, rather than all pathways by targeting NOS itself. Considerable research into the mechanisms of NOS-dependent toxicity has identified NOS effector pathways, many of which are dependent on the binding of specific NOS isoforms to binding partners that are important for delivering NO to certain intracellular signaling complexes. Here we will discuss various NOS isoform effector pathways that may be useful for therapeutic intervention, and which may be targetable by small molecule inhibitors of protein-protein interactions.
Molecular Basis for Specific Pathways Mediated by NOS
The finding that NO has a wide range of effects, both in neurons and in a variety of other cell types, has focused interest on the mechanism by which these effects are mediated. In the search for target proteins that mediate the effects of NO, guanylyl cyclase is often considered, in large part because it is the key effector of endothelial-produced NO in the process of vasorelaxation [135] . In fact, this enzyme was the first well-characterized target of NO and NO-releasing pharmaceuticals [135] . NO stimulates guanylyl cyclase by binding to iron in the heme moiety at the active site of the enzyme, leading to a conformational alteration that augments enzyme activity [136] . However, unlike vasorelaxation, which can be substantially blocked by inhibitors of guanylyl cyclase and stimulated by nonhydrolyzable cGMP analogues, many of the effects of NO in the brain are completely resistant to these drugs [137] .
Another reaction of NO in biological systems involves the formation of nitrosothiols [138, 139] , a modification of the sulfur atom on cysteine, also called S-nitrosation or Snitrosylation. NO exhibits a well-characterized reaction with O 2 to yield NO x such as NO 2 and N 2 O 3 , powerful electrophiles that S-nitrosylate cysteines. Indeed S-nitrosylation can be detected in biological tissue up to the mid-micromolar range [139, 140] .
Accumulating evidence suggests that S-nitrosylation plays a key role in physiological signal transduction, and, more recently, human disease. For example, S-nitrosylation of the protein parkin results in a loss of parkin's ubiquitin E3 ligase activity. Increased S-nitrosylation of parkin is found in mouse models of Parkinson's disease and in brains of patients with Parkinson's and diffuse Lewy body diseases [141, 142] . S-nitrosylation can also stimulate protein activity or lead to increased protein-protein interactions. An example of this was reported recently when S-nitrosylation of GAPDH was shown to elicit binding to Siah1, leading to nuclear translocation and, ultimately, apoptosis [143] . Other links between aberrant S-nitrosylation of specific proteins and disease have been implicated in arthritis, diabetes, cystic fibrosis, multiple sclerosis, and stroke [144] .
The reaction of NO with target proteins is highly regulated, with only specific proteins being S-nitrosylated, and in most cases, only a single cysteine within the target protein being modified [145] . This degree of specificity occurs despite the ability of NO to diffuse freely throughout both intra-and extra-cellular space, where it could react with any heme or cysteine residue. An emerging theme in NOS signaling is that the NOS isoforms are targeted to specific proteins that couple NOS isoforms to intracellular signaling complexes or subcellular localizations. These protein-protein interactions lead to locally high concentrations of NO, facilitating and providing specificity to S-nitrosylation reactions [138] . All three NOS isoforms have been shown to have unique protein binding partners in cells, and these interactions might explain how even a single NOS isoform can have both beneficial and detrimental effects in disease states, such as the case in sepsis. Small molecules that target these interactions might then offer an advantage over dimerization inhibitors or other isoform-specific inhibitors when used to control disease. Specific strategies are described below. iNOS iNOS has roles in the pathogenesis of both sepsis, which is primarily associated with hypotension and impaired organ perfusion, as well as inflammatory disorders, such as rheumatoid arthritis, asthma, and inflammatory bowel disease, which are associated with the generation of inflammatory mediators that cause tissue damage. In the case of these inflammatory disorders, NO, generated by iNOS, and prostaglandins, synthesized by the inducible cyclooxygenase COX-2, are key inflammatory mediators [146] .
Although NO has signaling and cytotoxic roles during inflammation, one function of NO is to induce prostaglandin production. This function of NO was first observed in 1993 when Salvemini, Needleman and colleagues showed that exogenous application of NO to COX-1 enriched sheep microsomal seminal vesicles resulted in augmented prostaglandin production [147] . Similarly, application of NO to fibroblasts expressing COX-2 resulted in enhanced prostaglandin production [147] . Additionally, in a macrophage cell line treated with inflammatory signals such as lipopolysaccharide to mimic physiological inflammatory diseases, iNOS and COX-2 were induced; however, application of iNOS inhibitors blocked release of prostaglandins [147] . The iNOS inhibitors that were used did not affect COX-2 enzymatic activity, indicating that COX-2 activity was dependent upon iNOS-generated NO.
Recent work indicates that the mechanism of iNOSmediated activation of COX-2 involves direct binding of iNOS to COX-2 and subsequent S-nitrosylation of critical cysteine residues in COX-2 [148] . S-nitrosylation of COX-2 directly enhanced prostaglandin synthesis [148] . Expression of peptide sequence derived from COX-2 that blocks the interaction of iNOS and COX-2 significantly reduces Snitrosylation of COX-2 and prostaglandin production in stimulated macrophage cell lines, without affecting NO generation from iNOS [148] . These data provide important proof-of-concept examples that inhibition of the iNOS-COX-2 interaction can regulate prostaglandin production without affecting other aspects of iNOS signaling. Importantly, COX-2 selective drugs have significant side effects that have limited their clinical use [149] . Drugs based on the COX-2 peptide that block the iNOS-COX-2 interaction may provide an alternative therapeutic approach towards iNOS and COX-2-associated diseases.
nNOS
Many of the actions of nNOS are mediated by specific protein-protein interactions involving the N-terminus of nNOS (Fig. 4) . The N-terminal domain of nNOS does not contribute to the enzymatic mechanism of the enzyme and does not have a counterpart in either the eNOS or iNOS isoforms [150] . This domain contains a PDZ domain, a protein interacting domain that mediates the interaction of nNOS with several target proteins, including PSD95 and CAPON (Carboxyl terminal PDZ ligand of nNOS) [151] . PDZ domains typically interact with specific sequences at the C-terminus of proteins, and the interaction includes recognition of the carboxyl group at the C-terminus. However, the interaction of nNOS and PSD95 involves an unusual PDZ-PDZ interaction. PSD95 itself contains three PDZ domains, and the third PDZ domain interacts with a beta hairpin "finger" structure at the C-terminal end of the nNOS PDZ domain [152] , leaving the peptide-binding interface of the nNOS PDZ domain intact [153] . There are also ligands for the nNOS PDZ domains. CAPON is probably the most studied and interacts via its C-terminal sequence. CAPON binding to nNOS prevents PSD95 binding to nNOS [154] , probably by sterically hindering access to the beta hairpin finger.
The interactions of nNOS with PSD95 and CAPON link nNOS to specific subcellular domains in the cell. PSD95 is enriched in postsynaptic densities of synapses, and PSD95 is coupled to NMDA receptors via its other PDZ domains. PSD95 thus acts as a tether that links nNOS to NMDA receptors [153] . Activation of NMDA receptors causes calcium influx and subsequent activation of nNOS. Coupling of nNOS to PSD95 is required for this functional coupling of NMDA receptor activation and nNOS activation [153, 155] , apparently by linking nNOS to NMDA receptor-gated calcium sources.
nNOS is also linked to other domains in the cell via CAPON. CAPON, like PSD95, appears to act as a tether that links nNOS to other proteins. CAPON interacts with synapsin, a component of synaptic vesicles on the presynaptic side of the synapse. Synapsin is enriched in presynaptic densities [156] , a site that is known functionally and by immunocytochemical studies to be enriched in nNOS [157, 158] . The coupling of nNOS to synapsin via CAPON may also be important for specifying the targets of S-nitrosylation since the actions of NO on synaptic vesicle release, in part, requires S-nitrosylation, and several synaptic vesicle machinery proteins have been implicated as S-nitrosylation targets [159] . The coupling of nNOS to synaptic vesicles by CAPON may position nNOS to efficiently regulate this process. The CAPON gene locus may also be genetically linked to schizophrenia [160] , consistent with the proposed role of CAPON in regulating neurotransmission.
The coupling of nNOS to Dexras1 is a key example of Snitrosylation facilitated by specific protein-protein interac-tions. In addition to synapsin, CAPON couples nNOS to a small ras-like G-protein, Dexras1 [161] . Dexras1 is activated by S-nitrosylation; however, this activation is greatly enhanced by the presence of CAPON and the concomitant formation of the ternary complex [161] . These studies suggest that efficient S-nitrosylation depends on the proximity of Dexras1 to the NO source, i.e., nNOS, presumably because of the higher local concentration of NO in the vicinity of the enzyme.
Because nNOS relies on specific protein-protein interactions to activate specific effector pathways, small molecules that target these protein-protein interactions are likely to have highly selective effects on NO signaling. In the case of excitotoxic signaling, peptide molecules that bind the PSD95 PDZ domain and block the heterodimerization of nNOS and PSD95 are effective in reducing toxicity associated with stroke [162] . Although this study utilized a peptide that mimicked endogenous ligands of the PSD95 PDZ domain, recent strategies for the development of nonpeptidic molecules that bind PDZ domains [163] may be useful to generate bioavailable compounds based on the inhibitory peptide. These compounds could then presumably be used for inhibiting the PSD95-nNOS interaction. Ultimately, these molecules could be used for therapy of stoke and other neurodegenerative disease.
In addition to targeting the PSD95 PDZ domain, small molecule ligands of the nNOS PDZ domain would be useful to block the binding of nNOS to CAPON. Small molecule ligands, unlike CAPON itself, would not be expected to affect the interaction of nNOS with PSD95 [153] , but would selectively affect nNOS regulation of synaptic vesicle release (via synapsin) as well as nNOS-dependent activation of Dexras1. Since excess NO release during excitotoxicity induces synaptic vesicle release, and further augmentation of excitotoxicity, this may be a particularly useful strategy to limit the extent of tissue damage during stroke.
An additional strategy for NOS inhibition is suggested by a protein inhibitor of nNOS, LC8 [164] . Crystallographic studies demonstrate that LC8 forms dimers that couple nNOS-derived peptides [165] . Although studies of the mechanism of LC8-mediated inhibition of nNOS have been impeded by its tendency to aggregate under certain purification conditions [166] , LC8-treated nNOS inhibits activity with concomitant formation of both high molecular weight nNOS aggregates and loose nNOS dimers or nNOS monomers [164] . LC8-mediated nNOS multimerization is consistent with LC8-mediated intermolecular nNOS interactions, while LC8-mediated nNOS destabilization might be due to a 2:2 LC8:nNOS intramolecular nNOS interaction followed by dimer dissociation. Conceivably, symmetric bifunctional molecules that bind each PDZ Fig. (4) . Scheme of protein-protein interactions involving neuronal nitric oxide synthase. Protein-protein interactions are critical to optimal NOS signaling. In the case of nNOS, direct binding of the nNOS beta-finger to the PSD95 PDZ domain results in coupling of nNOS to NMDA receptors, as well as NMDA receptor-gated calcium sources. This leads to efficient activation of nNOS by NMDA receptor agonists. nNOS is also a component of cytosolic multiprotein complexes which enhance nNOS signaling. For example, Dexras1, CAPON, and nNOS form a complex that places Dexras1 in proximity to nNOS. The juxtaposition of nNOS and Dexras1 by CAPON makes Dexras1 a preferred target for S-nitrosylation by nNOS-generated NO, presumably by the increased local concentration of NO in the vicinity of Dexras1.
domain within the nNOS dimer could induce conformational strain leading to nNOS monomerization and inactivation.
CONCLUSIONS
Despite the fact that NO has been implicated in a vast array of medical disorders, successful application of NOS inhibitors for medical treatment has remained elusive. It is difficult to definitively conclude that the failure of NOS inhibitors reflects their lack of selectivity in isoform targeting instead of their inability to inhibit specific effector pathways. Several advances, such as the dimerization inhibitors and L-Arg-based inhibitors that take advantage of isoform-specific structural features of the catalytic site, will be critical for distinguishing between these possibilities. Selective targeting of the interactions of the various NOS isoforms with specific intracellular proteins is likely to provide more discrete pharmacologic effects that can be tailored to specific medical diseases.
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